Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 7Genitourinary 6Myeloid 5Thoracic 4Head & Neck 3Gastrointestinal 2Breast 2Tumor-Agnostic 1Sarcoma 1Plasma cell 1Endocrine 1Dermatologic 1CNS 1

Conditions

Meningioma 1Memory Disorders 1Glioblastoma 1Cognitive Dysfunction 1Brain Neoplasms 1Astrocytoma 1

Interventions

Temozolomide 610Radiotherapy 388Bevacizumab 254Magnetic Resonance Spectroscopy 203Cyclophosphamide 177Carboplatin 159Radiosurgery 146Etoposide 132Radiation 121Irinotecan 115Vincristine 114Cisplatin 102Filgrastim 100Specimen Handling 88Nivolumab 87pembrolizumab 82Lomustine 81Topotecan 73Surgical Procedures, Operative 73Doxorubicin 60Melphalan 59Carmustine 57sargramostim 53Radiotherapy, Intensity-Modulated 53Isotretinoin 53Peripheral Blood Stem Cell Transplantation 52Granulocyte Colony-Stimulating Factor 50Erlotinib Hydrochloride 50Everolimus 48Chemotherapy, Adjuvant 48

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Pioglitazone × CNS × Clear all
NCT01151670 2018-08-01

Pioglitazone Hydrochloride in Preventing Radiation-Induced Cognitive Dysfunction in Treating Patients With Brain Tumors

Wake Forest University Health Sciences

Phase 1 Completed
18 enrolled
CNS

Astrocytoma, Brain Neoplasms, Glioblastoma, Memory Disorders, Meningioma, Cognitive Dysfunction

Data powered by HemOnc (CC BY 4.0) Colophon âš¡